NovoCure Limited
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Frank Leonard
- Full Time Employees
- 1,605
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Neuhofstrasse 21 St. Helier United Kingdom 6340
- IPO Date
- Oct 2, 2015
- CIK
- 0001645113
- Website
- novocure.com
- Similar Companies
- Business
- NovoCure Limited (Nasdaq: NVCR) is a global oncology company that develops, manufactures and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive anti-mitotic treatment delivered via wearable devices that disrupt cancer cell division in solid tumors. Its main commercialized products include Optune Gio, approved for adult patients with glioblastoma (GBM), and Optune Lua, approved for malignant pleural mesothelioma (MPM); in 2024, the U.S. FDA expanded approvals to include TTFields therapy concurrently with PD-1/PD-L1 inhibitors or docetaxel for metastatic non-small cell lung cancer (mNSCLC) following platinum-based therapy, and approved new Head Flexible Electrode (HFE) transducer arrays to enhance patient comfort in GBM treatment. The company conducts Phase 3 clinical trials such as PANOVA-3 (pancreatic cancer), LUNAR-2 and METIS (lung and brain metastases), and TRIDENT (ovarian cancer), targeting additional aggressive cancers. Founded in 2000 and headquartered in Baar, Switzerland, with U.S. operations in Portsmouth, New Hampshire, and R&D in Haifa, Israel, NovoCure operates in the United States, Germany, France, Japan, Greater China and other international markets. Recent developments include the January 2025 inauguration of new global headquarters in the Canton of Zug, Switzerland, to support expansion; a multi-tranche $400 million non-dilutive debt financing with Pharmakon Advisors, with $100 million drawn at closing and more available through 2025; and positive topline results from the Phase 3 PANOVA-3 trial demonstrating statistically significant overall survival improvement in unresectable pancreatic cancer.
Company News
NovoCure (NASDAQ:NVCR) and Ambu A/S (OTCMKTS:AMBBY) Head to Head Contrast
Novocure: A Mispriced Cash-Generating Biotech With Upside Potential
Reviewing NeurAxis (NASDAQ:NRXS) and NovoCure (NASDAQ:NVCR)
Critical Survey: Medline (NASDAQ:MDLN) & NovoCure (NASDAQ:NVCR)
Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
NovoCure Limited $NVCR Stake Trimmed by Corient Private Wealth LP
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Novocure Reports Patient Data Exposure in Cybersecurity Incident
Novocure Announces Upcoming Investor Events
Oncology firm Novocure says cyberattack exposed US patient records
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice
Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet
4 Healthcare Stocks to Watch as Defensive Demand Strengthens
NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade
Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospects
NovoCure: Why I'm Fading The Q2 Earnings Rally
NovoCure's Clean Beat Signals A Shift Toward Profitability (Rating Upgrade)